The Jetstream G3™ Calcium Study

Completed · Phase 4

Conditions studied: Peripheral Arterial Disease

In brief

To investigate the treatment effects with the Jetstream G3 System in moderate to severely calcified peripheral artery disease in the common femoral, superficial femoral or popliteal arteries using intravascular ultrasound (IVUS).

Key facts

Study ID

NCT01273623

Run by

Boston Scientific Corporation

People needed

55

Starts

2011-01-01

Expected to finish

2012-03-01

Last updated by the study team

2015-11-18

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient is ≥ 18 years of age.
• Patient has claudication determined to be due to femoropopliteal lesion(s) requiring revascularization.
• The target lesion(s) is/are located in the common femoral, superficial femoral or popliteal arteries.
• The reference vessel lumen (proximal to target lesion) is ≥ 3.0mm.
• The patient is an acceptable candidate for percutaneous intervention using the Jetstream G3 System in accordance with its labeled indications and instructions for use.
• The patient has signed approved informed consent.
• Moderate or severe vessel obstructive intraluminal calcification as demonstrated by IVUS and angiography.

You may not qualify if…

• Patient has an uncontrollable allergy to nitinol, stainless steel or other stent materials or to contrast agent.
• Patient is unable to take appropriate anti-platelet therapy.
• Patient has no distal runoff vessels.
• Deep wall calcium.
• Interventional treatment is intended for in-stent restenosis at the peripheral vascular site.
• Patient has target vessel with moderate or severe angulation (e.g., >30 degrees) or tortuosity at the treatment segment.
• Patient has a history of coagulopathy or hypercoagulable bleeding disorder.
• Patient is receiving hemodialysis or has impaired renal function (creatinine is > 2.5 mg/dl) at the time of treatment.
• Patient has evidence of intracranial or gastrointestinal bleeding within the past 3 months.
• Patient has had severe trauma, fracture, major surgery or biopsy of a parenchymal organ within the past 14 days.
• Patient is pregnant or nursing a child.
• Intended interventional treatment includes planned laser, brachytherapy or atherectomy procedure other than the Jetstream G3 System.

Where it is running

• Arizona Heart Institute — Phoenix, Arizona, United States
• Emory University — Atlanta, Georgia, United States
• St. John Hopital — Detroit, Michigan, United States
• Mercy Medical Center — Knoxville, Tennessee, United States
• Wheaton Franciscan Healthcare — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.